Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

16 Jan 2009 08:31

RNS Number : 7610L
ViaLogy PLC
16 January 2009
 



VIALOGY PLC ("VIALOGY" OR "THE COMPANY")

VIALOGY AND ATASCOSA EXTEND OIL PROJECT; SIGN COMMERCIAL CONTRACT

Friday, January 16, 2009LondonEngland. Vialogy PLC (LSE: VIY) announces today it has signed a contract with Atascosa Exploration LLC to analyze data from three separate oil prospects in south central Texas, known collectively as the Galba Unit. The analysis will determine size and boundaries of reservoirs, overall porosity maps, and optimal well locations. Using its patented QuantumRD™ processing, that exploits subtle variations in geoseismic noise to overcome limitations in current seismic data processing techniques, Vialogy will provide locations for between 6 to 9 wells at sites the companies estimate will be needed to produce the recoverable oil in place

The three prospects include both currently producing areas and new, undeveloped areas. According to Atascosa's geological and engineering estimates, these prospects potentially contain over a million barrels of oil recoverable. ViaLogy's responsibilities include overseeing new, high-resolution 3D seismic surveys, an integrated reservoir assessment, and maintaining reservoir models during the project's life cycle. The first well is planned for completion by Q1 2009. 

This expanded project replaces a previously announced single pilot well, and will accelerate QuantumRD's proof-of-concept across multiple wells in three different formations, achieving one of the company's key business objectives. In addition, the new technology promises to address a problem faced by the oil industry worldwide - drilling dry holes. In Texas itself, 4 out of 10 exploratory wells, including those drilled with the aid of seismic, fail to find gas or oil in economically producible quantities. Such abortive attempts are costly. According to US Dept. of Energy (DOE) Energy Information Administration (EIA) statistics, the 2006 average cost for drilling an on-shore dry hole in the US was over $450,000. 

Under the Atascosa contract, Vialogy will receive for its drill site analysis an interest in production. Atascosa and Vialogy have agreed on 5% of the working interest (WI) back-in after pay-out (BIAPO) to Vialogy in the first well on each prospect. That is, once all well development costs have been paid out, ViaLogy receives 5% of the working interest revenues going forward minus operating expenses. For subsequent wells on each of the three Galba Unit prospects, ViaLogy will receive a right to participate at cost for 5% of the working interest. 

Going forward, the companies have agreed to implement a pricing model for the QuantumRD service based on both a drill site analysis fee and an interest in the prospect. For this contracted project, once drilling is completed, an estimate of the total dollar value of ViaLogy's projected revenues will be possible.

Atascosa CEO, John Mullins, commented, "We have introduced QuantumRD into our critical decision path for determining well location. We believe the unique formation and porosity assessments can deliver revenue growth, and save on production expense. If we prove conclusively that by using the technology we can reduce the number of dry holes, I believe it will have a major impact on the industry." 

Vialogy CEO, Robert W. Dean, said: "We are delighted that Atascosa has decided to extend the use of QuantumRD into a broader exploration and production setting that will best show the capability of this technology, provide revenue, and justify a business model that Vialogy can carry forward."

In anticipation of a successful outcome ViaLogy is making plans to market QuantumRD extensively. 

ViaLogy

Robert W Dean, President & CEO - US (+1 703-589-3807) Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 

Atascosa Exploration LLC John D. Mullins, CEO (+1 210-402-3656) 

Nominated Advisor (Seymour Pierce) Mark Percy +44 (0) 20-7107-8000 

Brokers to ViaLogy PLC 

St. Helen's Capital +44 (0) 7628 5582

About ViaLogy: Network Centric Signal Processing ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTGUUUWGUPBURQ
Date   Source Headline
14th Dec 20217:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSNotice of Half-year results
18th Nov 20217:00 amRNSDPYD screening recommended in Spain
28th Oct 20217:00 amRNSRanger® Technology to be presented at Labroots
26th Oct 20217:00 amRNSHalf-year Trading update
29th Sep 20217:00 amRNSResult of AGM
28th Sep 20213:00 pmRNSAGM update
28th Sep 20217:00 amRNSAGM Statement
15th Sep 20217:00 amRNSShare option awards
1st Sep 20217:00 amRNSISO 15189:2012 accreditation received
1st Sep 20217:00 amRNSNotice of AGM and Annual Report 2021
19th Aug 202112:04 pmRNSCOVID-19 Surge testing contract
11th Aug 20217:01 amRNSEarn-out Milestone, Issue of Equity & TVR
11th Aug 20217:00 amRNSAudited Final results&unaudited Q1 business update
6th Aug 20217:00 amRNSConfirmation of Results Date
23rd Jul 20217:00 amRNSNotice of Results
1st Jul 202111:09 amRNSHolding(s) in Company
21st Jun 20217:00 amRNSSecond Strategic Partner for Coastal Genomics
18th Jun 20217:00 amRNSContract Award: DPYD testing kits for NHS Wales
17th Jun 20214:32 pmRNSExercise of Options
9th Jun 20217:00 amRNSMulti-year licence and supply agreement
21st May 20214:30 pmRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSDistribution Partnership
18th May 20217:00 amRNSLaunch of IONA Care NIPT service offering
17th May 20217:00 amRNSFurther testing service agreement for MHC
29th Apr 20217:00 amRNSFull year Trading update
26th Apr 20217:00 amRNSFurther National Microbiology Framework awards
19th Apr 20211:21 pmRNSFurther National Microbiology Framework contract
19th Apr 20217:00 amRNSNational Framework contract award
12th Apr 20217:00 amRNSEarn-out Milestone, Issue of Equity & TVR
6th Apr 20212:43 pmRNSTesting service agreement with MyHealthCheckedplc
6th Apr 20211:54 pmRNSAgreement with Boots for COVID-19 sample kits
29th Mar 20214:00 pmRNSCOVID-19 update
23rd Mar 20217:00 amRNSShare option exercises and awards
19th Mar 20217:00 amRNSTwin Pregnancy study published using IONA® Test
17th Mar 20217:00 amRNSAppointment of VP of Sales North America
11th Mar 20217:00 amRNSYourgene Genomic Services portfolio expansion
1st Mar 20217:00 amRNSFirst US Supply Agreement
22nd Feb 20217:00 amRNSPartnership with NPH
10th Feb 202110:51 amRNSCorrection: Director / PDMR Shareholding
10th Feb 20217:00 amRNSDirector/PDMR Shareholding
8th Feb 20217:00 amRNSTrading update
13th Jan 20217:00 amRNSDPYD screening recommended in Belgium
11th Jan 20217:00 amRNSClarigene® SARS-CoV-2 Product Update
8th Jan 20217:00 amRNSIssue of Share Options
24th Dec 20207:00 amRNSCOVID-19 update
17th Dec 20207:00 amRNSHalf-year Report
15th Dec 20207:00 amRNSNotice of Half-year Results
2nd Dec 20207:00 amRNSDPYD kits recommended by NHS England
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.